| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiotherapy Planning, Computer-Assisted | 14 | 2025 | 204 | 4.190 |
Why?
|
| Radiotherapy, Intensity-Modulated | 16 | 2025 | 188 | 4.190 |
Why?
|
| Radiotherapy, Conformal | 4 | 2025 | 88 | 2.500 |
Why?
|
| Phantoms, Imaging | 9 | 2020 | 484 | 1.870 |
Why?
|
| Thermoluminescent Dosimetry | 3 | 2020 | 5 | 1.550 |
Why?
|
| Radiotherapy Dosage | 19 | 2025 | 472 | 1.540 |
Why?
|
| Radiosurgery | 4 | 2020 | 317 | 1.440 |
Why?
|
| Bone Marrow | 8 | 2025 | 409 | 1.240 |
Why?
|
| Organs at Risk | 7 | 2023 | 48 | 1.150 |
Why?
|
| Brain Neoplasms | 3 | 2020 | 813 | 1.140 |
Why?
|
| Whole-Body Irradiation | 7 | 2025 | 70 | 1.050 |
Why?
|
| Fibrosarcoma | 2 | 2025 | 89 | 1.040 |
Why?
|
| Particle Accelerators | 4 | 2020 | 16 | 1.020 |
Why?
|
| Tumor Hypoxia | 3 | 2025 | 43 | 0.950 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2023 | 2585 | 0.920 |
Why?
|
| Transplantation Conditioning | 5 | 2025 | 383 | 0.860 |
Why?
|
| Monte Carlo Method | 4 | 2020 | 191 | 0.850 |
Why?
|
| Oxygen | 4 | 2025 | 769 | 0.790 |
Why?
|
| Photons | 2 | 2020 | 48 | 0.730 |
Why?
|
| Thyroiditis, Subacute | 1 | 2022 | 1 | 0.720 |
Why?
|
| Radiation Injuries | 4 | 2015 | 158 | 0.690 |
Why?
|
| Beryllium | 1 | 2019 | 1 | 0.630 |
Why?
|
| Lung | 3 | 2020 | 1366 | 0.590 |
Why?
|
| Bone and Bones | 1 | 2020 | 273 | 0.570 |
Why?
|
| Algorithms | 6 | 2020 | 1953 | 0.560 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 3476 | 0.550 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2025 | 939 | 0.540 |
Why?
|
| Models, Theoretical | 1 | 2019 | 494 | 0.510 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2020 | 318 | 0.500 |
Why?
|
| Oscillometry | 1 | 2016 | 25 | 0.490 |
Why?
|
| Hematologic Neoplasms | 3 | 2023 | 372 | 0.470 |
Why?
|
| Optical Imaging | 1 | 2016 | 51 | 0.470 |
Why?
|
| Head | 1 | 2016 | 131 | 0.460 |
Why?
|
| Radiation Dosage | 4 | 2020 | 229 | 0.460 |
Why?
|
| Absorption, Radiation | 1 | 2015 | 4 | 0.460 |
Why?
|
| Skin Physiological Phenomena | 1 | 2015 | 18 | 0.450 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2015 | 25 | 0.450 |
Why?
|
| Hematologic Diseases | 2 | 2015 | 77 | 0.440 |
Why?
|
| Body Burden | 2 | 2012 | 10 | 0.430 |
Why?
|
| Respiration | 1 | 2016 | 269 | 0.430 |
Why?
|
| Models, Chemical | 2 | 2008 | 185 | 0.420 |
Why?
|
| Radiometry | 2 | 2012 | 60 | 0.420 |
Why?
|
| Metal Nanoparticles | 2 | 2010 | 35 | 0.400 |
Why?
|
| Gold | 2 | 2010 | 44 | 0.400 |
Why?
|
| Neoplasms | 3 | 2015 | 3169 | 0.380 |
Why?
|
| Whole-Body Counting | 1 | 2012 | 4 | 0.360 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 608 | 0.360 |
Why?
|
| Bone Marrow Diseases | 1 | 2012 | 37 | 0.360 |
Why?
|
| Deoxyglucose | 1 | 2010 | 39 | 0.320 |
Why?
|
| Feasibility Studies | 4 | 2020 | 756 | 0.320 |
Why?
|
| Cell Line, Tumor | 7 | 2025 | 2755 | 0.320 |
Why?
|
| Contrast Media | 3 | 2020 | 988 | 0.320 |
Why?
|
| X-Ray Microtomography | 1 | 2010 | 101 | 0.310 |
Why?
|
| Humans | 36 | 2025 | 93515 | 0.310 |
Why?
|
| DNA | 2 | 2008 | 1265 | 0.300 |
Why?
|
| Myeloablative Agonists | 3 | 2025 | 38 | 0.290 |
Why?
|
| Busulfan | 3 | 2025 | 42 | 0.290 |
Why?
|
| Radiotherapy, Image-Guided | 2 | 2020 | 62 | 0.290 |
Why?
|
| Computer Simulation | 4 | 2016 | 1118 | 0.280 |
Why?
|
| Radiation Protection | 1 | 2008 | 27 | 0.280 |
Why?
|
| Fiducial Markers | 2 | 2020 | 11 | 0.280 |
Why?
|
| Pelvic Bones | 1 | 2008 | 45 | 0.270 |
Why?
|
| Free Radicals | 1 | 2008 | 71 | 0.270 |
Why?
|
| Nucleotides | 1 | 2008 | 93 | 0.260 |
Why?
|
| Vidarabine | 2 | 2025 | 93 | 0.260 |
Why?
|
| Nitric Oxide | 3 | 2013 | 281 | 0.250 |
Why?
|
| DNA Damage | 2 | 2013 | 389 | 0.240 |
Why?
|
| Calibration | 2 | 2019 | 106 | 0.220 |
Why?
|
| Transplantation, Homologous | 2 | 2025 | 1014 | 0.220 |
Why?
|
| Equipment Design | 2 | 2016 | 416 | 0.210 |
Why?
|
| Mice | 5 | 2025 | 12269 | 0.210 |
Why?
|
| Radiation Injuries, Experimental | 2 | 2015 | 41 | 0.200 |
Why?
|
| Endometrial Neoplasms | 1 | 2006 | 227 | 0.200 |
Why?
|
| Deoxyribose | 1 | 2002 | 2 | 0.180 |
Why?
|
| Animals | 7 | 2025 | 28155 | 0.180 |
Why?
|
| Chemoradiotherapy | 2 | 2015 | 326 | 0.180 |
Why?
|
| Hydroxyl Radical | 1 | 2002 | 36 | 0.180 |
Why?
|
| Pulmonary Fibrosis | 2 | 2015 | 152 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2025 | 2544 | 0.170 |
Why?
|
| Saliva | 1 | 2021 | 124 | 0.160 |
Why?
|
| Multiple Myeloma | 2 | 2017 | 338 | 0.160 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2010 | 137 | 0.160 |
Why?
|
| Cesium Radioisotopes | 1 | 2019 | 12 | 0.160 |
Why?
|
| Printing, Three-Dimensional | 1 | 2020 | 50 | 0.160 |
Why?
|
| Cobalt Radioisotopes | 1 | 2019 | 19 | 0.160 |
Why?
|
| Adult | 11 | 2025 | 27918 | 0.150 |
Why?
|
| Cell Hypoxia | 1 | 2020 | 187 | 0.150 |
Why?
|
| Middle Aged | 12 | 2025 | 27573 | 0.150 |
Why?
|
| Female | 17 | 2025 | 48702 | 0.140 |
Why?
|
| Aged | 9 | 2025 | 20434 | 0.140 |
Why?
|
| Anus Neoplasms | 2 | 2009 | 37 | 0.140 |
Why?
|
| Retrospective Studies | 6 | 2025 | 10164 | 0.140 |
Why?
|
| Movement | 1 | 2020 | 304 | 0.130 |
Why?
|
| Young Adult | 4 | 2025 | 6930 | 0.130 |
Why?
|
| Adenocarcinoma | 3 | 2013 | 1173 | 0.130 |
Why?
|
| Adolescent | 4 | 2025 | 9606 | 0.130 |
Why?
|
| Rectum | 2 | 2008 | 149 | 0.120 |
Why?
|
| Combined Modality Therapy | 5 | 2017 | 1723 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2020 | 1261 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 2715 | 0.120 |
Why?
|
| Adaptation, Physiological | 3 | 2013 | 329 | 0.120 |
Why?
|
| Motion | 1 | 2016 | 94 | 0.120 |
Why?
|
| Pandemics | 1 | 2022 | 873 | 0.120 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2015 | 13 | 0.120 |
Why?
|
| Workflow | 1 | 2016 | 77 | 0.120 |
Why?
|
| Software | 1 | 2020 | 670 | 0.120 |
Why?
|
| Periodicity | 1 | 2016 | 113 | 0.120 |
Why?
|
| Morpholines | 1 | 2015 | 61 | 0.110 |
Why?
|
| Transducers | 1 | 2015 | 37 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2022 | 7061 | 0.110 |
Why?
|
| Urinary Bladder | 2 | 2008 | 260 | 0.110 |
Why?
|
| Radiation-Protective Agents | 1 | 2015 | 98 | 0.110 |
Why?
|
| Equipment Failure Analysis | 1 | 2015 | 88 | 0.110 |
Why?
|
| Male | 12 | 2025 | 44557 | 0.110 |
Why?
|
| Pyrazoles | 1 | 2015 | 150 | 0.110 |
Why?
|
| Unrelated Donors | 1 | 2014 | 47 | 0.110 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2014 | 67 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2015 | 236 | 0.100 |
Why?
|
| Lung Neoplasms | 3 | 2015 | 2365 | 0.100 |
Why?
|
| Prospective Studies | 1 | 2022 | 4560 | 0.100 |
Why?
|
| Serine C-Palmitoyltransferase | 1 | 2012 | 4 | 0.090 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2012 | 15 | 0.090 |
Why?
|
| Regression Analysis | 2 | 2010 | 579 | 0.090 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2012 | 79 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 2 | 2017 | 259 | 0.090 |
Why?
|
| Time Factors | 3 | 2016 | 5410 | 0.090 |
Why?
|
| DNA Repair | 1 | 2013 | 361 | 0.090 |
Why?
|
| Prognosis | 1 | 2019 | 3911 | 0.090 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2012 | 216 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 1922 | 0.080 |
Why?
|
| Cell Survival | 2 | 2010 | 1004 | 0.080 |
Why?
|
| Tongue Neoplasms | 1 | 2010 | 51 | 0.080 |
Why?
|
| Prostatic Neoplasms | 2 | 2020 | 1775 | 0.080 |
Why?
|
| Melphalan | 2 | 2023 | 98 | 0.080 |
Why?
|
| Brain | 1 | 2020 | 2391 | 0.080 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2009 | 41 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 1 | 2010 | 281 | 0.080 |
Why?
|
| Biological Transport | 1 | 2010 | 404 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 641 | 0.070 |
Why?
|
| Recurrence | 2 | 2025 | 1190 | 0.070 |
Why?
|
| Radioisotopes | 1 | 2008 | 39 | 0.070 |
Why?
|
| Anthropometry | 1 | 2008 | 75 | 0.070 |
Why?
|
| Tissue Distribution | 1 | 2008 | 291 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2008 | 193 | 0.070 |
Why?
|
| Electron Spin Resonance Spectroscopy | 2 | 2020 | 324 | 0.070 |
Why?
|
| Gastrointestinal Tract | 1 | 2009 | 195 | 0.070 |
Why?
|
| Forecasting | 1 | 2008 | 293 | 0.070 |
Why?
|
| Apoptosis | 1 | 2013 | 1721 | 0.060 |
Why?
|
| Water | 1 | 2008 | 307 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2010 | 1077 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2010 | 585 | 0.060 |
Why?
|
| Intestine, Small | 1 | 2008 | 310 | 0.060 |
Why?
|
| Posture | 1 | 2006 | 123 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 423 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 2017 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2013 | 3502 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 1133 | 0.060 |
Why?
|
| Brachytherapy | 1 | 2006 | 126 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2006 | 314 | 0.060 |
Why?
|
| Vagina | 1 | 2006 | 177 | 0.050 |
Why?
|
| Hysterectomy | 1 | 2006 | 167 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 876 | 0.050 |
Why?
|
| Infant | 1 | 2010 | 3220 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2008 | 1353 | 0.050 |
Why?
|
| Graft vs Host Disease | 1 | 2025 | 365 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 3830 | 0.050 |
Why?
|
| Nitric Oxide Donors | 2 | 2012 | 13 | 0.040 |
Why?
|
| Glutathione S-Transferase pi | 2 | 2012 | 18 | 0.040 |
Why?
|
| Hydrogen | 1 | 2002 | 53 | 0.040 |
Why?
|
| Stochastic Processes | 1 | 2002 | 75 | 0.040 |
Why?
|
| Models, Biological | 1 | 2008 | 1768 | 0.040 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2021 | 38 | 0.040 |
Why?
|
| X-Ray Film | 1 | 2020 | 37 | 0.040 |
Why?
|
| Polyesters | 1 | 2020 | 44 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 56 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2020 | 47 | 0.040 |
Why?
|
| Viral Load | 1 | 2021 | 154 | 0.040 |
Why?
|
| Copper | 1 | 2020 | 79 | 0.040 |
Why?
|
| Nucleic Acid Conformation | 1 | 2002 | 342 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 296 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 285 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2012 | 730 | 0.040 |
Why?
|
| Oximetry | 1 | 2020 | 90 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 887 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 109 | 0.040 |
Why?
|
| Child | 1 | 2010 | 7355 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 3110 | 0.040 |
Why?
|
| Mitomycin | 2 | 2009 | 29 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2012 | 454 | 0.040 |
Why?
|
| Pelvis | 2 | 2010 | 100 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 349 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 297 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 104 | 0.030 |
Why?
|
| Fluorouracil | 2 | 2009 | 524 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 359 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1448 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2012 | 1741 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 109 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 2015 | 175 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2015 | 352 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1524 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 636 | 0.030 |
Why?
|
| Allografts | 1 | 2014 | 205 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2013 | 273 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2017 | 9099 | 0.020 |
Why?
|
| Acute Disease | 1 | 2015 | 841 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 2012 | 123 | 0.020 |
Why?
|
| Sphingosine | 1 | 2012 | 73 | 0.020 |
Why?
|
| Thorax | 1 | 2012 | 78 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 889 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 691 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1161 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 1007 | 0.020 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2010 | 3 | 0.020 |
Why?
|
| Nitroso Compounds | 1 | 2010 | 12 | 0.020 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2010 | 15 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2010 | 22 | 0.020 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2010 | 35 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1701 | 0.020 |
Why?
|
| X-Rays | 1 | 2010 | 138 | 0.020 |
Why?
|
| Hemoglobin A | 1 | 2010 | 8 | 0.020 |
Why?
|
| Oxidants | 1 | 2010 | 86 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 293 | 0.020 |
Why?
|
| Platelet Count | 1 | 2010 | 90 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2010 | 164 | 0.020 |
Why?
|
| Survival Rate | 1 | 2014 | 1948 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2010 | 210 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2012 | 347 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2010 | 192 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2010 | 210 | 0.020 |
Why?
|
| Robotic Surgical Procedures | 1 | 2015 | 368 | 0.020 |
Why?
|
| Probability | 1 | 2010 | 355 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 784 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 1028 | 0.020 |
Why?
|
| Relative Biological Effectiveness | 1 | 2008 | 14 | 0.020 |
Why?
|
| Nuclear Medicine | 1 | 2008 | 12 | 0.020 |
Why?
|
| Neutrophils | 1 | 2010 | 324 | 0.020 |
Why?
|
| Linear Models | 1 | 2009 | 413 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 1053 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 3435 | 0.020 |
Why?
|
| Cisplatin | 1 | 2010 | 568 | 0.020 |
Why?
|
| Leukopenia | 1 | 2007 | 64 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 1338 | 0.020 |
Why?
|
| Neutropenia | 1 | 2007 | 209 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2007 | 189 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2010 | 811 | 0.020 |
Why?
|
| Anemia | 1 | 2007 | 134 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 579 | 0.010 |
Why?
|
| Risk Factors | 1 | 2015 | 5899 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2009 | 2850 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2009 | 1073 | 0.010 |
Why?
|
| United States | 1 | 2015 | 7622 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 2303 | 0.010 |
Why?
|